Slide 1: ASX Announcement: Cogstate Investor Presentation
ASX Announcement 24 July 2020 For personal use only Cogstate Investor Presentation Cogstate (ASX.CGS) has today released an investor presentation that provides a summary of the current state of the business, with a focus on the quarterly results for the period ended 30 June 2020 as well as the recen
Slide 2: Investor Presentation: June Quarter Business Update
Investor Presentation For personal use only June Quarter Business Update 24 July 2020 Brad O’Connor Cogstate CEO © 2020 Cogstate Ltd. All rights reserved.
Slide 3: Themes for this meeting
Themes for this meeting For personal use only Sales and Revenue Cashflow Growing Portfolio of Significant Partners Growth in sales has delivered Cashflow positive quarter Potentially significant sales revenue increase in 2H20 distribution channel for Cogstate SHARP TURNAROUND IN SALES $10.3M CASH BA
Slide 4: Founding Vision
For personal use only Founding Vision To develop an assessment of brain health that could be used anywhere for any purpose 4
Slide 5: What sets Cogstate apart
Proven ability to commercialize highly sensitive What sets computerized cognitive assessments backed by science and carefully designed for the rigor of clinical research Cogstate apart For personal use only Inclusion of our computerized endpoint in major longitudinal and natural history studies, est
Slide 6: Revenue Streams
For personal use only Revenue Streams Clinical Trials Healthcare Growing and consolidating strongly on a Subscription based software revenue model project revenue model that provides great sold through strategic partners who have visibility and predictability of revenue other revenue tied to adoptio
Slide 7: Clinical Trials Revenue Recognition
For personal use only Clinical Trials Revenue Recognition SALES CONTRACTS REVENUE REVENUE BACKLOG 1 Clinical Trial = 1 Sales Contract Recognised over length of trial as The amount contracted in prior software is released or as services periods that has not yet been Value from $0.1m to $10m+ performe
Slide 8: Record-high sales contracts executed
Record-high sales contracts executed For personal use only Historically low level of sales contracts in FY19 $46 million Clinical Trials sales contracts executed for FY20: • Most successful year on record • Over 150% improvement on FY19 • 28% improvement on the previous record set in FY18 All result
Slide 9: Revenue
Revenue For personal use only Total revenue of $7.6 million for 4Q20: • 21% increase on the prior quarter • 43% increase on the prior corresponding period. All results presented in US$ Revenue 1Q20 2Q20 3Q20 4Q20 FY20 FY19 US$ m US$ m US$ m US$ m US$ m US$ m Clinical Trials 3.80 4.46 5.73 7.02 21.01
Slide 10: Record-high revenue backlog
Record-high revenue backlog For personal use only Revenue backlog at 30 June 2020 was $39.4 million • $15.35m expected to be recognised in FY21 • Compared to $10.83m at the same time last year (42% improvement) All results presented in US$ Contracted Clinical Trials Revenue - Expected Run-Off and Hi
Slide 11: Net cash inflow of $3m for the June quarter
Net cash inflow of $3m for the June quarter For personal use only Operating cash inflow of $1.1 million Receipt of Paycheck Protection Program loan of $2.4 million All results presented in US$ PPP Loan Terms • Unsecured, guaranteed by the US Small Business Administration • Fixed rate of interest at
Slide 12: Partnering as a critical growth strategy
For personal use only Partnering as a critical growth strategy 12
Slide 13: ERT eCOA platform
VERT A singledevi ind clinical outcome as: REQUEST A DEMO 13
Slide 14: ERT + Cogstate Integration and Marketing Partnership
ERT + Cogstate Integration and Marketing Partnership For personal use only Providing potentially significant distribution channel for Cogstate Cogstate computerised assessments deployed on ERT eCOA technology platform 2019: 75% of all FDA approved drugs came from studies supported by ERT Seamless so
Slide 15: ERT + Cogstate Integration and Marketing Partnership
ERT + Cogstate Integration and Marketing Partnership For personal use only Cogstate expertise and technology : making the complex simple Not just great science… Cogstate technology provides efficiency for ERT customers • 33% reduction in start-up timelines • 66% reduction in test administration time
Slide 16: Business & Financial Outlook
COVID-19 Update Business & Beginning to see signs of initiation of new clinical trials For personal use only Financial Outlook Financial Results Release of FY20 financial results on 26 August 2020 ERT Launch Begin support of ERT sales channel Healthcare Opportunity Interest in upcoming announcements
Slide 17: For personal use only
G Cogstate Ajuo asn feuosied 105